Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Dolby Laboratories Inc (DLB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive partnerships.
Compared to Estimates, Dolby Laboratories (DLB) Q1 Earnings: A Look at Key Metrics
Dolby Laboratories (DLB) reported $357 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.1%. EPS of $1.14 for the same period compares to $1.01 a year ago.
Dolby Laboratories, Inc. (NYSE:DLB) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for standing by.
Dolby's Q1 Earnings & Revenues Surpass Estimates, Increase Y/Y
DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.
Dolby Laboratories Earnings Review: Q1 Summary
Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same period last year. In the previous quarter, the company beat on EPS by $0.11, resulting in a 16.0% increase change in the share price the following day.
Dolby Laboratories: Fiscal Q1 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share. The creator and licensor of audio, video and voice technologies posted revenue of $357 million in the period,
Here's Why We Think Dolby Laboratories (NYSE:DLB) Is Well Worth Watching
The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Dolby Laboratories' future EPS 100% free.
Earnings call transcript: Dolby Labs beats Q1 2025 EPS forecast, stock rises
Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations and witnessing a positive market reaction. The company achieved earnings per share (EPS) of $1.
Dolby Laboratories (DLB) Tops Q1 Earnings and Revenue Estimates
Dolby Laboratories (DLB) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.
Dolby Laboratories Inc (DLB) Q1 2025 Earnings Report Preview: What To Expect
Dolby Laboratories Inc (NYSE:DLB) is set to release its Q1 2025 earnings on Jan 29, 2025. The consensus estimate for Q1 2025 revenue is $346.15 million, and the earnings are expected to come in at $0.
Dolby Laboratories Q1 2025 Earnings Preview
Dolby Laboratories (NYSE:DLB) is scheduled to announce Q1 earnings results on Wednesday, January 29th, after market close. The consensus EPS Estimate is $0.98 (-3.0% Y/Y) and the consensus Revenue Estimate is $345.
2h
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
news.stocktradersdaily
6d
How the (DLB) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
stocknews
13d
Is Dolby Laboratories a Sound Investment in Audio Technology?
Audio technology is evolving at a rapid pace with growing investments in cutting-edge technologies and innovations. Dolby ...
2h
CervoMed provides update on neflamapimod DLB program
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Knowridge
5d
This test could achieve early diagnosis of dementia with Lewy bodies
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback